Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label and exploratory clinical study of Anlotinib Hydrochloride
Capsules combined with Sintilimab injection in the treatment of advanced Hepatocellular
Carcinoma (HCC).
In oder to observe and evaluate the efficacy and safety of Anlotinib Hydrochloride Capsules
combined with Sintilimab injection. Subjects with pathological confirmed Hepatocellular
Carcinoma will be enrolled.
21 days as a treatment cycle, Anlotinib 12mg/day(D1-D14 ) and Sintilimab injection 200mg Q3W
(D1). Sintilimab injection will be administered until disease progressioncor un-tolerable
toxicity. Anlotinib will be administered until disease progression. If anlotinib is not
tolerated, the dose can be reduced to 10mg or 8mg ,until un-tolerable toxicity again.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University